Travel-Acquired Illnesses

Published on 14/03/2015 by admin

Filed under Emergency Medicine

Last modified 14/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 946 times

48

Travel-Acquired Illnesses

Sources of Information

The Centers for Disease Control and Prevention (CDC) publishes several authoritative sources of information on travel medicine. Health Information for International Travel (the “yellow book”) is updated annually. Two other periodicals, the weekly Morbidity and Mortality Weekly Report (MMWR) and Summary of Health Information for International Travel (the “blue sheet,” published biweekly), provide updated information on the status of immunization recommendations, worldwide disease outbreaks, and changes in health conditions. A reliable way to obtain current travel health information, including vaccine requirements, malaria chemoprophylaxis, and disease outbreaks for various regions of the world, is to consult the CDC Travelers’ Health website at http://wwwnc.cdc.gov/travel/. See Chapter 49 for more information on immunizations for travel. For nonmedical information of interest to the traveler, the U.S. State Department can be accessed at http://travel.state.gov/. Additional resources for travel medicine information are listed at the end of the chapter.

Aside from traveler’s diarrhea (see Chapter 44), traffic-related accidents, and purified protein derivative conversion, the major travel-acquired illnesses in descending order from most to least common are as follows:

These disorders are often preventable if the traveler takes specific precautions or prophylactic agents. Influenza, acute HIV infection, Legionella, and poliomyelitis are not discussed in this chapter because they are generally preventable with standard immunizations, or their medical management is similar to that in developed countries. Travelers at risk for HIV exposure should consider bringing 72 hours of postexposure prophylaxis medication, because many developing countries do not have access to HIV drugs.

Dengue Fever

Dengue virus is a single-stranded ribonucleic acid (RNA) flavivirus that is transmitted by the day-biting urban mosquito Aedes aegypti or the jungle mosquito Aedes albopictus. A. aegypti is the principal vector for dengue viruses worldwide. Viral transmission is maintained through a mosquito-human cycle without a major animal reservoir.

Signs and Symptoms (Compare Dengue With Malaria in Table 48-1)

Table 48-1

Clinical Illness in Malaria and Dengue Fever

SIGNS AND SYMPTOMS MALARIA DENGUE FEVER
Fever +++ +++
Chills +++ ++
Headache +++ +++
Malaise   ++
Anorexia   ++
Nausea, vomiting ++ ++
Abdominal pain ++  
Myalgia ++ ++
Arthralgia   ++
Backache +  
Dark urine +  

+++, >90% of patients; ++, >50% of patients; +, <10% of patients.

1. Clinically, may range from undifferentiated viral symptoms with fever and mild respiratory/gastrointestinal symptoms to dengue hemorrhagic fever

2. Incubation period: 4 to 6 days, although may be as long as 14 days

3. Early prodromal symptoms of fever (temperature usually greater than 39° C [102.2° F]), myalgias, headache, arthralgias, and rash. May also have gastrointestinal symptoms of nausea and vomiting

4. After several days, often maculopapular or morbilliform rash spreading outward from chest

5. Dengue can progress to severe forms, referred to as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Severe DHF/DSS may progress to circulatory failure with shock and spontaneous bleeding from almost any site, most commonly the skin, nose, and gastrointestinal tract

6. After infection, patients often develop extreme fatigue persisting for weeks or months

7. DHF/DSS is unlikely in travelers not previously infected with dengue

8. Awareness of the local epidemiology of DHF/DSS is important in establishing the diagnosis. Definitive diagnosis of all forms requires serologic examination (antibody identification via enzyme-linked immunosorbent assay [ELISA] or polymerase chain reaction [PCR]) or viral isolation from serum

9. Predictors of more severe disease manifestations, including DHF/DSS, include serotype (DEN-2 is the most severe), prior exposure, age, malnutrition, and genetic factors such as human leukocyte antigen (HLA) type

Yellow Fever

Yellow fever is one of the viral hemorrhagic fevers. It is caused by a single-stranded RNA flavivirus that is transmitted by mosquitoes. The liver is the principal target organ. All recent cases of American yellow fever were acquired in the jungle environment; however, urban transmission continues to occur in Africa.

Signs and Symptoms

1. May appear as an undifferentiated viral syndrome

2. Specific diagnosis in the wilderness is extremely difficult; clinical suspicion is based on immune status, geographic distribution of the disease, travel history, and characteristic triphasic fever, as follows:

a. Infection phase: After 3 to 6 days of incubation period, onset of headache, photophobia, fever, malaise, back pain, epigastric pain, anorexia, and vomiting. May also have “Faget sign” (bradycardia occurring at the height of the fever), conjunctival injection, and a coated tongue with pink edges

b. Remission phase: The 3 to 4 days of infection phase is followed by up to 48 hours of brief remission

c. Intoxication phase (up to 15% of individuals infected with yellow fever virus): Onset of jaundice, fever, encephalopathy, and in severe cases, hypotension, shock, oliguria, coma, and multiorgan failure. Hemorrhage usually manifested as hematemesis, but bleeding from multiple sites possible

d. Signs of a poor prognosis include early onset of the intoxication phase, hypotension, severe hemorrhage with disseminated intravascular coagulation, renal failure, shock, and coma

Rabies Exposure

Rabies exists almost everywhere in the world with the exception of Antarctica and a few island nations. Most cases of human disease in the developing world result from multiple, deep bites to the face, scalp, or upper extremities from an unimmunized canine. In more developed countries, however, the majority of rabies transmission occurs from wild animal carriers (see Chapter 42). Travelers who plan on spending more than 1 month in regions at high risk for rabies should consider preexposure rabies immunization. CDC recommendations for rabies prophylaxis can be found at http://www.cdc.gov/diseases/rabies.html. Rabies is almost universally fatal within a few weeks of symptom onset. If a potential rabies exposure occurs, immunized patients will require only two subsequent rabies immunization boosters on days 0 and 3 post exposure with close follow up. Patients without preexposure immunizations should receive rabies immune globulin and rabies immunization as outlined in Chapter 43.

Hepatitis Viruses

The causes of hepatitis may be divided into two groups. First, the lettered viruses now include hepatitis A to G. These are associated with defined clinical syndromes and elevated liver function test results. Second, other organisms that cause hepatitis as part of a more systemic infection include Epstein-Barr virus, cytomegalovirus, toxoplasmosis, and leptospirosis.

Hepatitis A

Hepatitis A virus (HAV) is transmitted mainly through the fecal-oral route, either by person-to-person contact or by ingestion of contaminated food or water. Occasional cases are associated with exposure to nonhuman primates. HAV is endemic worldwide, but developing regions have a significantly higher prevalence. In most instances, resolution of the acute disease is permanent, but rare cases of relapse have been noted. Death from HAV is rare. After natural infection, HAV antibodies confer immunity. HAV patients are infectious for approximately 2 weeks before the onset of symptoms. Viral shedding declines with the onset of jaundice. The patient is typically not infectious 1 to 2 weeks after the onset of clinical disease.